David Emanuel, MD; Isabel Cunningham, MD; Kethy Jules-Elysee, MD; Joel A. Brochstein, MD; Nancy A. Kernan, MD; Joseph Laver, MD; Diane Stover, MD; Dorothy A. White, MD; Anna Fels, MD; Bruce Polsky, MD; Hugo Castro-Malaspina, MD; Joanne R. Peppard, MT; Patricia Bartus, BS; Ulrich Hammerling, PhD; Richard J. O'Reilly, MD
Study Objective: To assess the efficacy of the combination of the antiviral agent ganciclovir (9-1,3 dihydroxy-2-propoxymethylguanine) and high-dose intravenous immune globulin for treating cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation.
Design: Nonrandomized prospective trial of combined treatment with two drugs; findings in these patients were compared with those in control patients treated with either of the two drugs alone.
Setting: Medical, pediatric, and intensive care units of a tertiary-care cancer treatment center.
Patients: Consecutive cases of 10 patients in the study group and of 11 patients in a historical control group with evidence of cytomegalovirus pneumonia after bone marrow transplantation for treatment of leukemia or congenital immune deficiency.
Interventions: Study Group (10 patients): ganciclovir, 2. 5 mg/kg body weight, three times daily for 20 days, plus intravenous immune globulin, 500 mg/kg every other day for ten doses. Patients were then given ganciclovir, 5 mg/kg · d three to five times a week for 20 more doses, and intravenous immune globulin, 500 mg/kg twice a week for 8 more doses. Control Group (11 patients): ganciclovir alone (2 patients), 5 mg/kg twice a day for 14 to 21 days; cytomegalovirus hyperimmune globulin (5 patients), 400 mg/kg · d for 10 days; and intravenous immune globulin (4 patients), 400 mg/kg · d for 10 days.
Measurements and Main Results: Responses were observed in all patients treated with combination therapy; 7 of 10 patients were alive and well, and had no recurrence of disease at a median of 10 months after therapy. No therapeutic benefit was observed, and none of the 11 patients treated with either ganciclovir or intravenous immune globulin alone survived (P = 0.001 by Fisher exact test).
Conclusions: Ganciclovir, when combined with high-dose intravenous immune globulin, appears to have significantly altered the outcome of patients with cytomegalovirus pneumonia after allogeneic bone marrow transplantation.
Learn more about subscription options.
Register Now for a free account.
Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J, et al. Cytomegalovirus Pneumonia after Bone Marrow Transplantation Successfully Treated with the Combination of Ganciclovir and High-Dose Intravenous Immune Globulin. Ann Intern Med. 1988;109:777-782. doi: 10.7326/0003-4819-109-10-777
Download citation file:
Published: Ann Intern Med. 1988;109(10):777-782.
Hematology/Oncology, Infectious Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only